1118 related articles for article (PubMed ID: 17909199)
21. FDA drug approval summary: bevacizumab (Avastin) plus Carboplatin and Paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer.
Cohen MH; Gootenberg J; Keegan P; Pazdur R
Oncologist; 2007 Jun; 12(6):713-8. PubMed ID: 17602060
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib in advanced non-small cell lung cancer: efficacy and safety findings of the global phase IV Tarceva Lung Cancer Survival Treatment study.
Reck M; van Zandwijk N; Gridelli C; Baliko Z; Rischin D; Allan S; Krzakowski M; Heigener D
J Thorac Oncol; 2010 Oct; 5(10):1616-22. PubMed ID: 20736854
[TBL] [Abstract][Full Text] [Related]
23. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
[TBL] [Abstract][Full Text] [Related]
24. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
Socinski MA; Stinchcombe TE; Moore DT; Gettinger SN; Decker RH; Petty WJ; Blackstock AW; Schwartz G; Lankford S; Khandani A; Morris DE
J Clin Oncol; 2012 Nov; 30(32):3953-9. PubMed ID: 23045594
[TBL] [Abstract][Full Text] [Related]
25. An indirect comparison of the efficacy of bevacizumab plus carboplatin and paclitaxel versus pemetrexed with cisplatin in patients with advanced or recurrent non-squamous adenocarcinoma non-small cell lung cancer.
Nuijten MJ; Aultman R; Carpeño Jde C; Vergnenègre A; Chouaid C; Walzer S; Siebert U
Curr Med Res Opin; 2011 Nov; 27(11):2193-201. PubMed ID: 21970659
[TBL] [Abstract][Full Text] [Related]
26. Treatment rationale and study design for a randomized trial of pemetrexed/carboplatin followed by maintenance pemetrexed versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with advanced non-small-cell lung cancer of nonsquamous histology.
Zinner RG; Saxman SB; Peng G; Monberg MJ; Ortuzar WI
Clin Lung Cancer; 2010 Sep; 11(5):352-7. PubMed ID: 20837462
[TBL] [Abstract][Full Text] [Related]
27. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer.
Gianni L; Romieu GH; Lichinitser M; Serrano SV; Mansutti M; Pivot X; Mariani P; Andre F; Chan A; Lipatov O; Chan S; Wardley A; Greil R; Moore N; Prot S; Pallaud C; Semiglazov V
J Clin Oncol; 2013 May; 31(14):1719-25. PubMed ID: 23569311
[TBL] [Abstract][Full Text] [Related]
28. Everolimus and erlotinib as second- or third-line therapy in patients with advanced non-small-cell lung cancer.
Papadimitrakopoulou VA; Soria JC; Jappe A; Jehl V; Klimovsky J; Johnson BE
J Thorac Oncol; 2012 Oct; 7(10):1594-601. PubMed ID: 22968184
[TBL] [Abstract][Full Text] [Related]
29. Pemetrexed, oxaliplatin and bevacizumab as first-line treatment in patients with stage IV non-small cell lung cancer.
Mir O; Boudou-Rouquette P; Giroux J; Chapron J; Alexandre J; Gibault L; Ropert S; Coriat R; Durand JP; Burgel PR; Dusser D; Goldwasser F
Lung Cancer; 2012 Jul; 77(1):104-9. PubMed ID: 22364783
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.
Sequist LV; von Pawel J; Garmey EG; Akerley WL; Brugger W; Ferrari D; Chen Y; Costa DB; Gerber DE; Orlov S; Ramlau R; Arthur S; Gorbachevsky I; Schwartz B; Schiller JH
J Clin Oncol; 2011 Aug; 29(24):3307-15. PubMed ID: 21768463
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of first-line bevacizumab plus chemotherapy in elderly patients with advanced or recurrent nonsquamous non-small cell lung cancer: safety of avastin in lung trial (MO19390).
Laskin J; Crinò L; Felip E; Franke F; Gorbunova V; Groen H; Jiang GL; Reck M; Schneider CP
J Thorac Oncol; 2012 Jan; 7(1):203-11. PubMed ID: 22173662
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of nanoparticle albumin-bound paclitaxel, carboplatin, and bevacizumab in first-line patients with advanced nonsquamous non-small cell lung cancer.
Reynolds C; Barrera D; Jotte R; Spira AI; Weissman C; Boehm KA; Pritchard S; Asmar L
J Thorac Oncol; 2009 Dec; 4(12):1537-43. PubMed ID: 19887966
[TBL] [Abstract][Full Text] [Related]
33. Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer.
Ross HJ; Blumenschein GR; Aisner J; Damjanov N; Dowlati A; Garst J; Rigas JR; Smylie M; Hassani H; Allen KE; Leopold L; Zaks TZ; Shepherd FA
Clin Cancer Res; 2010 Mar; 16(6):1938-49. PubMed ID: 20215545
[TBL] [Abstract][Full Text] [Related]
34. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
[TBL] [Abstract][Full Text] [Related]
35. A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE; Santos ES; Webb RT; Wade J; Brito RA; Karr M; Kennah A; Childs BH
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1103-10. PubMed ID: 24057043
[TBL] [Abstract][Full Text] [Related]
36. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
[TBL] [Abstract][Full Text] [Related]
37. Erlotinib and bevacizumab in newly diagnosed performance status 2 or elderly patients with nonsquamous non-small-cell lung cancer, a phase II study of the Hoosier Oncology Group: LUN04-77.
Riggs H; Jalal SI; Baghdadi TA; Bhatia S; McClean J; Johnson C; Yu M; Taber D; Harb W; Hanna N
Clin Lung Cancer; 2013 May; 14(3):224-9. PubMed ID: 23102811
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
[TBL] [Abstract][Full Text] [Related]
39. Prospective assessment of pemetrexed or pemetrexed plus platinum in combination with gefitinib or erlotinib in patients with acquired resistance to gefitinib or erlotinib: a phase II exploratory and preliminary study.
Yu S; Zhang B; Xiang C; Shu Y; Wu H; Huang X; Yu Q; Yin Y; Guo R
Clin Lung Cancer; 2015 Mar; 16(2):121-7. PubMed ID: 25450874
[TBL] [Abstract][Full Text] [Related]
40. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
Herbst RS; Giaccone G; Schiller JH; Natale RB; Miller V; Manegold C; Scagliotti G; Rosell R; Oliff I; Reeves JA; Wolf MK; Krebs AD; Averbuch SD; Ochs JS; Grous J; Fandi A; Johnson DH
J Clin Oncol; 2004 Mar; 22(5):785-94. PubMed ID: 14990633
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
